News

The NHS Business Services Authority (NHSBSA) celebrates Race Equality Week 2024 by participating in the Lead the Change Virtual Event, featuring an opening from Chief Executive Michael Brodie, and a presentation from Data Warehouse ETL Developer and Shadow Board Member Sam Ubanatu.

More than 500,000 Hormone Replacement Therapy Prescription Prepayment Certificates (HRT PPCs) have now been purchased since the launch on 1 April 2023.

The NHS Business Services Authority (NHSBSA) has been awarded full provider status by the General Optical Council (GOC). The accreditation recognises the NHSBSA as a trusted provider of Continuous Professional Development (CPD) opportunities for Ophthalmic contractors.

NHS Business Services Authority (NHSBSA) has released its latest Medicines Used in Mental Health (England) report, now including new data from July to September 2023.

NHS Business Services Authority (NHSBSA) has released a report on 'Prescribing Costs in Hospitals and the Community for England in 2022-23'.

Many people go through the menopause every year, experiencing symptoms such as low mood, anxiety, hot flushes and difficulty sleeping. Some symptoms can be severe and have a negative impact on everyday life.

NHS Business Services Authority has published figures on community pharmacies and appliance contractors in England.

NHS Business Services Authority (NHSBSA) has been given Carer Confident status by Carers UK for its excellent work in supporting staff.

NHS Business Services Authority (NHSBSA) has released its latest Medicines Used in Mental Health (England) report, now including new data from April to June 2023.

NHS Business Services Authority (NHSBSA), which has its headquarters in Newcastle, has come 64th out of 100, in the Inspiring Workplaces Awards first-ever global rankings.

NHS Business Services Authority (NHSBSA) has come 64th out of 100, in the Inspiring Workplaces Awards first-ever global rankings.

NHS Business Service Authority's (NHSBSA) 'Dependency Forming Medicines - England 2015/16 to 2022/23' report shows that in 2022/23, the cost of prescribed dependency forming medicines was £380 million. This was a 51% decrease from 2015/16 when the cost was £780 million.